145 related articles for article (PubMed ID: 35137340)
21. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods.
Ackerman SJ; Rein AL; Blute M; Beusterien K; Sullivan EM; Tanio CP; Manyak MJ; Strauss MJ
Urology; 2000 Dec; 56(6):972-80. PubMed ID: 11113743
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
23. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
24. Using cost-effectiveness analysis in policy formulation in human service organizations.
Holosko MJ; Dobrowolsky J; Feit MD
J Health Soc Policy; 1989; 1(1):43-60. PubMed ID: 10313498
[TBL] [Abstract][Full Text] [Related]
25. Application of an economic evaluation approach to making regulatory decisions regarding access to medicines: advantages, challenges and recommendations.
Parkinson B; Cutler H
Aust Health Rev; 2022 Apr; 46(2):143-149. PubMed ID: 34903326
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
27. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
28. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
29. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
McCullagh L; Schmitz S; Barry M; Walsh C
Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
[TBL] [Abstract][Full Text] [Related]
30. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
31. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
32. Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods.
Groot Koerkamp B; Myriam Hunink MG; Stijnen T; Weinstein MC
Health Econ; 2006 Apr; 15(4):383-92. PubMed ID: 16389669
[TBL] [Abstract][Full Text] [Related]
33. Exploring uncertainty in cost-effectiveness analysis.
Claxton K
Pharmacoeconomics; 2008; 26(9):781-98. PubMed ID: 18767898
[TBL] [Abstract][Full Text] [Related]
34. Addressing risk preferences in cost-effectiveness analyses.
Zivin JG; Bridges JF
Appl Health Econ Health Policy; 2002; 1(3):135-9. PubMed ID: 14619264
[TBL] [Abstract][Full Text] [Related]
35. Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.
Hagiwara Y; Shiroiwa T
Med Decis Making; 2022 Jul; 42(5):672-683. PubMed ID: 35172648
[TBL] [Abstract][Full Text] [Related]
36. Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.
Hernández Alava M; Wailoo A; Pudney S; Gray L; Manca A
Health Technol Assess; 2020 Jun; 24(34):1-68. PubMed ID: 32613941
[TBL] [Abstract][Full Text] [Related]
37. A cost-utility analysis of sacral anterior root stimulation (SARS) compared with medical treatment in patients with complete spinal cord injury with a neurogenic bladder.
Morlière C; Verpillot E; Donon L; Salmi LR; Joseph PA; Vignes JR; Bénard A
Spine J; 2015 Dec; 15(12):2472-83. PubMed ID: 26291400
[TBL] [Abstract][Full Text] [Related]
38. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
Sculpher M; Claxton K
Value Health; 2005; 8(4):433-46. PubMed ID: 16091019
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
